Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHAD WHYTE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1427222959
CMS profile
291271
Location
OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$115,509.01

496 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $34,557.09 75
Biohaven Pharmaceuticals, Inc. $30,874.75 119
Lilly USA, LLC $25,272.50 40
Amgen Inc. $9,996.19 22
Lundbeck LLC $7,225.80 18
Teva Pharmaceuticals USA, Inc. $3,377.47 37
Allergan, Inc. $1,904.54 28
Novartis Pharmaceuticals Corporation $290.20 30
Biogen, Inc. $164.31 13
UCB, Inc. $132.24 11
Genentech USA, Inc. $119.58 12
Eisai Inc. $110.63 9
Almatica Pharma LLC $90.04 4
Greenwich Biosciences, Inc. $89.53 3
Janssen Pharmaceuticals, Inc $89.13 4
UPSHER-SMITH LABORATORIES LLC $78.27 4
JAZZ PHARMACEUTICALS INC. $77.46 5
Mallinckrodt Hospital Products Inc. $76.98 3
GRT US Holding, Inc. $76.67 4
Kyowa Kirin, Inc. $75.45 4
Adamas Pharmaceuticals, Inc. $75.39 4
GENZYME CORPORATION $73.27 4
Neurelis, Inc. $68.73 3
Sunovion Pharmaceuticals Inc. $61.89 8
MDD US Operations, LLC $59.04 2
ACADIA Pharmaceuticals Inc $55.19 3
Avanir Pharmaceuticals, Inc. $42.91 3
ARBOR PHARMACEUTICALS, INC. $40.30 3
MITSUBISHI TANABE PHARMA AMERICA, INC. $34.28 2
Neurocrine Biosciences, Inc. $33.67 2
EMD Serono, Inc. $32.15 2
Alexion Pharmaceuticals, Inc. $31.99 2
CATALYST PHARMACEUTICALS, INC. $23.22 1
Supernus Pharmaceuticals, Inc. $23.11 2
CSL Behring $22.57 1
Acorda Therapeutics, Inc $22.27 1
Merck Sharp & Dohme Corporation $20.16 1
Celgene Corporation $18.79 1
PFIZER INC. $17.55 1
GE HEALTHCARE $16.68 1
Ipsen Biopharmaceuticals, Inc $15.31 1
BOSTON SCIENTIFIC CORPORATION $14.87 1
Takeda Pharmaceuticals U.S.A., Inc. $14.23 1
Amneal Pharmaceuticals LLC $12.61 1

Page 2 of 10; records 51–100 of 496 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHAD WHYTE

NPI 1427222959 · CMS profile ID 291271

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

OMAHA, NE

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 10; records 51–100 of 496 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1427222959?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHAD WHYTE, NPI 1427222959, CMS profile ID 291271. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 10; records 51–100 of 496 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1427222959?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). CHAD WHYTE, NPI 1427222959, CMS profile ID 291271. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 10; records 51–100 of 496 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1427222959?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
CHAD WHYTE, NPI 1427222959, CMS profile ID 291271, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 10; records 51–100 of 496 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1427222959?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

496 matching records · $115,509.01 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 496 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 496.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $18.5711/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796251011 CMS
AbbVie Inc. $2,400.0011/18/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796251013 CMS
AbbVie Inc. $17.8511/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796251015 CMS
AbbVie Inc. $46.1511/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796251017 CMS
AbbVie Inc. $10.6911/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796251005 CMS
Amgen Inc. $23.2811/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825208635 CMS
Lilly USA, LLC $1,500.0011/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818900747 CMS
Lilly USA, LLC $575.0011/16/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818900749 CMS
Lundbeck LLC $116.9111/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845940647 CMS
Biohaven Pharmaceuticals, Inc. $16.7411/15/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655539 CMS
Allergan, Inc. $3.6111/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792984073 CMS
Biohaven Pharmaceuticals, Inc. $8.7111/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655537 CMS
CSL Behring $22.5711/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 820255393 CMS
AbbVie Inc. $22.6111/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796251003 CMS
Eisai Inc. $17.9911/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818035173 CMS
Lilly USA, LLC $105.7411/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818900751 CMS
Teva Pharmaceuticals USA, Inc. $4.9411/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839578813 CMS
Teva Pharmaceuticals USA, Inc. $5.6911/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839578815 CMS
Sunovion Pharmaceuticals Inc. $6.5411/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821917731 CMS
AbbVie Inc. $3.7011/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796251001 CMS
Amgen Inc. $13.3511/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825208627 CMS
Biohaven Pharmaceuticals, Inc. $13.1811/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655535 CMS
Allergan, Inc. $2.4711/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792984071 CMS
AbbVie Inc. $26.2411/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796250999 CMS
Biohaven Pharmaceuticals, Inc. $7.6011/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655533 CMS
Biohaven Pharmaceuticals, Inc. $10.4311/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655529 CMS
Biohaven Pharmaceuticals, Inc. $1,275.0011/04/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655531 CMS
Lundbeck LLC $6.4811/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845940645 CMS
AbbVie Inc. $21.8111/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796250997 CMS
Biohaven Pharmaceuticals, Inc. $16.2811/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655527 CMS
Lundbeck LLC $5.5911/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845940643 CMS
GENZYME CORPORATION $12.4111/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843657851 CMS
Genentech USA, Inc. $7.8211/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 835895597 CMS
Novartis Pharmaceuticals Corporation $6.6011/02/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813361847 CMS
Biohaven Pharmaceuticals, Inc. $14.6011/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655525 CMS
GRT US Holding, Inc. $17.3411/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841347337 CMS
Biohaven Pharmaceuticals, Inc. $3.3510/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655523 CMS
Lundbeck LLC $13.2510/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845940641 CMS
Almatica Pharma LLC $12.5010/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842243061 CMS
Biohaven Pharmaceuticals, Inc. $6.5710/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655521 CMS
AbbVie Inc. $3.8310/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796250995 CMS
Biogen, Inc. $0.6410/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827829065 CMS
Biogen, Inc. $20.2310/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827829067 CMS
Novartis Pharmaceuticals Corporation $1.5410/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813361843 CMS
Lilly USA, LLC $12.9310/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818998933 CMS
Sunovion Pharmaceuticals Inc. $5.0110/26/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 821927921 CMS
AbbVie Inc. $25.8910/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796250993 CMS
Biohaven Pharmaceuticals, Inc. $11.4010/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852655519 CMS
AbbVie Inc. $3.8510/22/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796250987 CMS
AbbVie Inc. $1,920.0010/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 796250989 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $103,924.79 520
PY2020 $102,934.49 381
PY2021 $115,509.01 496
PY2022 $90,359.43 428
PY2023 $88,776.43 423
PY2024 $48,431.85 289
PY2025 $96,722.60 309

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $382,464.45 287
PY2024 Principal investigator $212,234.45 143
PY2023 Recipient $6,113.25 2
PY2023 Principal investigator $36,987.50 6

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

287 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202533681
Principal investigator 1 ABBVIE INC. $1,440.00 12/31/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-attack Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202533683
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Episodic Migraine in Pediatric Subjects 6-17 years of age. No dispute reported 06/30/2026 1202533685
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Multicenter, Open-label, Extension Study to Evaluate the Long-term Safety and Tolerability of Atogepant in Pediatric Subjects 6 to 17 years of age with Migraine No dispute reported 06/30/2026 1202533687
Principal investigator 1 ABBVIE INC. $728.76 12/31/2025 Non-covered Recipient Entity
COGNITIVE CLINICAL TRIALS LLC
A Phase 3, Multicenter, 12-Week, Double Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Atogepant for the Preventive Treatment of Chronic Migraine in Pediatric Subjects 12 to 17 Years of Age No dispute reported 06/30/2026 1202533689
Principal investigator 1 ABBVIE INC. $3,800.00 12/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202531784
Principal investigator 1 Ipsen Innovation $3,500.00 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286960
Principal investigator 1 Ipsen Innovation $66.00 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286962
Principal investigator 1 Ipsen Innovation $264.00 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286966
Principal investigator 1 Ipsen Innovation $724.81 12/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286968
Principal investigator 1 Ipsen Innovation $41.43 12/12/2025 Non-covered Recipient Entity
Cct Research Papillion Research Center
A Multicentre, Randomised, Double-blind, Placebo-controlled, Dose Escalation and Dose Finding Phase II Study to Evaluate the Safety and Efficacy of IPN10200 in the Prevention of Episodic or Chronic Migraine in Adults No dispute reported 06/30/2026 1184294695
Principal investigator 1 ABBVIE INC. $141.75 12/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202530214
Principal investigator 1 PFIZER INC. $2,862.35 12/11/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228811673
Principal investigator 1 PFIZER INC. $2,493.75 12/11/2025 Non-covered Recipient Entity
Cognitive Clinical Trials LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228811679
Principal investigator 1 ABBVIE INC. $2,708.25 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202527640
Principal investigator 1 ABBVIE INC. $1,718.10 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202527642
Principal investigator 1 ABBVIE INC. $856.00 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202527644
Principal investigator 1 ABBVIE INC. $1,690.50 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202527646
Principal investigator 1 ABBVIE INC. $2,500.00 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202527648
Principal investigator 1 ABBVIE INC. $9,700.25 12/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202528406
Principal investigator 1 PFIZER INC. $1,108.10 12/04/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228811703
Principal investigator 1 Ipsen Innovation $56.00 12/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286956
Principal investigator 1 Ipsen Innovation $70.00 12/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286958
Principal investigator 1 Ipsen Innovation $719.60 12/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286964
Principal investigator 1 Ipsen Innovation $28.00 12/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286970
Principal investigator 1 Ipsen Innovation $14.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286924
Principal investigator 1 Ipsen Innovation $66.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286926
Principal investigator 1 Ipsen Innovation $14.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286928
Principal investigator 1 Ipsen Innovation $14.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286930
Principal investigator 1 Ipsen Innovation $14.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286934
Principal investigator 1 Ipsen Innovation $500.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286936
Principal investigator 1 Ipsen Innovation $66.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286938
Principal investigator 1 Ipsen Innovation $14.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286940
Principal investigator 1 Ipsen Innovation $132.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286942
Principal investigator 1 Ipsen Innovation $66.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286946
Principal investigator 1 Ipsen Innovation $132.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286950
Principal investigator 1 Ipsen Innovation $14.00 11/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286954
Principal investigator 1 Ipsen Innovation $1,008.81 11/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286932
Principal investigator 1 Ipsen Innovation $1,700.36 11/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286944
Principal investigator 1 Ipsen Innovation $1,008.81 11/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286948
Principal investigator 1 Ipsen Innovation $1,008.81 11/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286952
Principal investigator 1 PFIZER INC. $2,393.80 11/24/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228817780
Principal investigator 1 ABBVIE INC. $840.00 11/13/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202524179
Principal investigator 1 ABBVIE INC. $138.00 11/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202523371
Principal investigator 1 PFIZER INC. $11,408.55 11/06/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228817789
Principal investigator 1 ABBVIE INC. $1,590.00 11/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202522303
Principal investigator 1 ABBVIE INC. $6,679.20 11/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522305
Principal investigator 1 ABBVIE INC. $6,902.25 11/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202522369
Principal investigator 1 ABBVIE INC. $2,690.31 11/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202522371
Principal investigator 1 ABBVIE INC. $100.00 11/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202520601
Principal investigator 1 ABBVIE INC. $454.80 11/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202520647
Principal investigator 1 Ipsen Innovation $1,008.81 10/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286892
Principal investigator 1 Ipsen Innovation $1,008.81 10/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286906
Principal investigator 1 Ipsen Innovation $1,982.18 10/27/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286918
Principal investigator 1 Ipsen Innovation $70.00 10/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286896
Principal investigator 1 Ipsen Innovation $56.00 10/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286898
Principal investigator 1 Ipsen Innovation $42.00 10/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286900
Principal investigator 1 Ipsen Innovation $280.00 10/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286902
Principal investigator 1 Ipsen Innovation $22.88 10/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286910
Principal investigator 1 ABBVIE INC. $229.50 10/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202516711
Principal investigator 1 Ipsen Innovation $66.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286894
Principal investigator 1 Ipsen Innovation $66.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286904
Principal investigator 1 Ipsen Innovation $132.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286908
Principal investigator 1 Ipsen Innovation $132.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286912
Principal investigator 1 Ipsen Innovation $132.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286914
Principal investigator 1 Ipsen Innovation $66.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286916
Principal investigator 1 Ipsen Innovation $132.00 10/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286920
Principal investigator 1 ABBVIE INC. $4,030.25 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202514183
Principal investigator 1 ABBVIE INC. $876.30 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202515845
Principal investigator 1 ABBVIE INC. $5,313.00 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202515847
Principal investigator 1 ABBVIE INC. $756.00 10/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202515855
Principal investigator 1 PFIZER INC. $550.00 10/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228823782
Principal investigator 1 PFIZER INC. $1,000.00 10/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228823815
Principal investigator 1 PFIZER INC. $1,717.60 10/09/2025 Non-covered Recipient Entity
Qcare Site Services Inc
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228823821
Principal investigator 1 Ipsen Innovation $1,696.66 09/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286868
Principal investigator 1 Ipsen Innovation $1,008.81 09/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286870
Principal investigator 1 Ipsen Innovation $1,008.81 09/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286874
Principal investigator 1 Ipsen Innovation $1,008.81 09/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286876
Principal investigator 1 Ipsen Innovation $1,008.81 09/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286880
Principal investigator 1 Ipsen Innovation $1,982.18 09/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286888
Principal investigator 1 Ipsen Innovation $450.00 09/23/2025 Non-covered Recipient Entity
Cct Research Papillion Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294693
Principal investigator 1 Ipsen Innovation $264.00 09/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286864
Principal investigator 1 Ipsen Innovation $66.00 09/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286884
Principal investigator 1 Ipsen Innovation $264.00 09/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286886
Principal investigator 1 Ipsen Innovation $140.00 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286866
Principal investigator 1 Ipsen Innovation $56.00 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286872
Principal investigator 1 Ipsen Innovation $28.00 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286878
Principal investigator 1 Ipsen Innovation $56.00 09/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286882
Principal investigator 1 ABBVIE INC. $2,259.75 09/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202508920
Principal investigator 1 ABBVIE INC. $897.00 09/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202508922
Principal investigator 1 ABBVIE INC. $1,590.00 09/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202508924
Principal investigator 1 ABBVIE INC. $5,002.50 09/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202508926
Principal investigator 1 ABBVIE INC. $2,970.00 09/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202508928
Principal investigator 1 ABBVIE INC. $420.00 08/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202506419
Principal investigator 1 Ipsen Innovation $1,696.66 08/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286848
Principal investigator 1 Ipsen Innovation $1,700.36 08/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286854
Principal investigator 1 Ipsen Innovation $1,008.81 08/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286858
Principal investigator 1 PFIZER INC. $6,913.55 08/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228827091
Principal investigator 1 Ipsen Innovation $140.00 08/13/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286830
Principal investigator 1 Ipsen Innovation $658.81 08/13/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286836
Principal investigator 1 Ipsen Innovation $66.00 08/13/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286840
Principal investigator 1 Ipsen Innovation $126.00 08/13/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286844
Principal investigator 1 Ipsen Innovation $264.00 08/13/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286846
Principal investigator 1 ABBVIE INC. $607.20 08/07/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202503885
Principal investigator 1 ABBVIE INC. $3,894.36 08/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202503013
Principal investigator 1 ABBVIE INC. $2,308.00 08/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202503015
Principal investigator 1 ABBVIE INC. $1,656.00 08/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202503017
Principal investigator 1 ABBVIE INC. $3,322.00 08/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202503019
Principal investigator 1 ABBVIE INC. $2,997.00 08/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202503021
Principal investigator 1 PFIZER INC. $550.00 08/04/2025 Non-covered Recipient Entity
Cognitive Clinical Trials LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228826977
Principal investigator 1 Ipsen Innovation $22.88 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286832
Principal investigator 1 Ipsen Innovation $420.00 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286834
Principal investigator 1 Ipsen Innovation $33.00 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286838
Principal investigator 1 Ipsen Innovation $132.00 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286842
Principal investigator 1 Ipsen Innovation $33.00 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286850
Principal investigator 1 Ipsen Innovation $99.00 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286852
Principal investigator 1 Ipsen Innovation $66.00 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286856
Principal investigator 1 Ipsen Innovation $198.00 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286860
Principal investigator 1 Ipsen Innovation $198.00 08/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286862
Principal investigator 1 Ipsen Innovation $450.00 07/30/2025 Non-covered Recipient Entity
Cct Research Papillion Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294689
Principal investigator 1 Ipsen Innovation $300.00 07/30/2025 Non-covered Recipient Entity
Cct Research Papillion Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294691
Principal investigator 1 Ipsen Innovation $1,008.81 07/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286790
Principal investigator 1 Ipsen Innovation $1,560.83 07/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286794
Principal investigator 1 Ipsen Innovation $1,982.18 07/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286814
Principal investigator 1 Ipsen Innovation $1,008.81 07/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286816
Principal investigator 1 Ipsen Innovation $1,008.81 07/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286828
Principal investigator 1 ABBVIE INC. $1,800.00 07/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202499526
Principal investigator 1 ABBVIE INC. $500.00 07/23/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202499310
Principal investigator 1 Ipsen Innovation $264.00 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286792
Principal investigator 1 Ipsen Innovation $66.00 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286802
Principal investigator 1 Ipsen Innovation $66.00 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286804
Principal investigator 1 Ipsen Innovation $132.00 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286806
Principal investigator 1 Ipsen Innovation $132.00 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286808
Principal investigator 1 Ipsen Innovation $32.00 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286810
Principal investigator 1 Ipsen Innovation $2,683.56 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286812
Principal investigator 1 Ipsen Innovation $132.00 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286818
Principal investigator 1 Ipsen Innovation $132.00 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286820
Principal investigator 1 Ipsen Innovation $2,683.56 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286822
Principal investigator 1 Ipsen Innovation $66.00 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286824
Principal investigator 1 Ipsen Innovation $66.00 07/17/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286826
Principal investigator 1 ABBVIE INC. $165.00 07/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202498198
Principal investigator 1 ABBVIE INC. $1,310.40 07/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202497592
Principal investigator 1 ABBVIE INC. $1,666.00 07/02/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202494523
Principal investigator 1 ABBVIE INC. $7,728.00 07/02/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202494525
Principal investigator 1 ABBVIE INC. $48.30 07/02/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202494653
Principal investigator 1 ABBVIE INC. $1,997.55 07/02/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202494655
Principal investigator 1 Ipsen Innovation $1,008.81 06/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286770
Principal investigator 1 Ipsen Innovation $1,700.36 06/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286772
Principal investigator 1 Ipsen Innovation $1,041.48 06/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286774
Principal investigator 1 Ipsen Innovation $1,982.18 06/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286776
Principal investigator 1 Ipsen Innovation $1,560.83 06/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286778
Principal investigator 1 Ipsen Innovation $1,008.81 06/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286780
Principal investigator 1 Ipsen Innovation $1,008.81 06/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286782
Principal investigator 1 Ipsen Innovation $1,008.81 06/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286784
Principal investigator 1 Ipsen Innovation $1,008.81 06/30/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286786
Principal investigator 1 ABBVIE INC. $3,800.00 06/18/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202492303
Principal investigator 1 ABBVIE INC. $4,000.00 06/12/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202491353
Principal investigator 1 ABBVIE INC. $48.30 06/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202490903
Principal investigator 1 ABBVIE INC. $100.00 06/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202490105
Principal investigator 1 ABBVIE INC. $1,587.00 06/04/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202490107
Principal investigator 1 ABBVIE INC. $11,060.45 06/03/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202489515
Principal investigator 1 ABBVIE INC. $2,808.30 06/03/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202489517
Principal investigator 1 ABBVIE INC. $8,638.00 06/03/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202489519
Principal investigator 1 ABBVIE INC. $20,444.70 06/03/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202489625
Principal investigator 1 ABBVIE INC. $500.00 05/29/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Adverse Events of Oral Atogepant Tablets in Pediatric Participants (6 to 17 Years of Age) With Episodic Migraine No dispute reported 06/30/2026 1202486893
Principal investigator 1 Ipsen Innovation $150.48 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286724
Principal investigator 1 Ipsen Innovation $1,008.81 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286726
Principal investigator 1 Ipsen Innovation $1,696.66 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286728
Principal investigator 1 Ipsen Innovation $2,098.07 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286734
Principal investigator 1 Ipsen Innovation $1,008.81 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286736
Principal investigator 1 Ipsen Innovation $1,008.81 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286738
Principal investigator 1 Ipsen Innovation $1,008.81 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286746
Principal investigator 1 Ipsen Innovation $1,008.81 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286748
Principal investigator 1 Ipsen Innovation $1,008.81 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286752
Principal investigator 1 Ipsen Innovation $1,008.81 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286754
Principal investigator 1 Ipsen Innovation $2,683.56 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286766
Principal investigator 1 Ipsen Innovation $1,008.81 05/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286768
Principal investigator 1 ABBVIE INC. $138.00 05/22/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202485813
Principal investigator 1 ABBVIE INC. $3,500.00 05/20/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202485483
Principal investigator 1 ABBVIE INC. $138.00 05/15/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202485037
Principal investigator 1 ABBVIE INC. $607.20 05/14/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202484823
Principal investigator 1 Ipsen Innovation $132.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286710
Principal investigator 1 Ipsen Innovation $1,102.40 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286712
Principal investigator 1 Ipsen Innovation $33.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286714
Principal investigator 1 Ipsen Innovation $66.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286716
Principal investigator 1 Ipsen Innovation $66.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286718
Principal investigator 1 Ipsen Innovation $22.88 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286720
Principal investigator 1 Ipsen Innovation $66.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286722
Principal investigator 1 Ipsen Innovation $33.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286730
Principal investigator 1 Ipsen Innovation $22.88 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286732
Principal investigator 1 Ipsen Innovation $350.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286740
Principal investigator 1 Ipsen Innovation $66.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286742
Principal investigator 1 Ipsen Innovation $22.88 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286744
Principal investigator 1 Ipsen Innovation $132.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286750
Principal investigator 1 Ipsen Innovation $66.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286756
Principal investigator 1 Ipsen Innovation $33.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286760
Principal investigator 1 Ipsen Innovation $66.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286762
Principal investigator 1 Ipsen Innovation $66.00 05/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286764
Principal investigator 1 ABBVIE INC. $138.00 05/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202481597
Principal investigator 1 Ipsen Innovation $1,700.36 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286674
Principal investigator 1 Ipsen Innovation $1,696.66 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286676
Principal investigator 1 Ipsen Innovation $150.48 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286678
Principal investigator 1 Ipsen Innovation $1,008.81 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286680
Principal investigator 1 Ipsen Innovation $1,008.81 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286682
Principal investigator 1 Ipsen Innovation $1,008.81 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286684
Principal investigator 1 Ipsen Innovation $1,560.83 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286686
Principal investigator 1 Ipsen Innovation $1,560.83 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286694
Principal investigator 1 Ipsen Innovation $1,008.81 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286696
Principal investigator 1 Ipsen Innovation $1,041.48 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286698
Principal investigator 1 Ipsen Innovation $1,008.81 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286700
Principal investigator 1 Ipsen Innovation $1,008.81 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286702
Principal investigator 1 Ipsen Innovation $2,683.56 04/28/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286704
Principal investigator 1 ABBVIE INC. $37.57 04/24/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202479278
Principal investigator 1 Ipsen Innovation $300.00 04/24/2025 Non-covered Recipient Entity
Cct Research Papillion Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294685
Principal investigator 1 Ipsen Innovation $90.00 04/24/2025 Non-covered Recipient Entity
Cct Research Papillion Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294687
Principal investigator 1 PFIZER INC. $283.10 04/24/2025 Non-covered Recipient Entity
Cognitive Clinical Trials LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228832296
Principal investigator 1 ABBVIE INC. $960.00 04/16/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202477055
Principal investigator 1 Ipsen Innovation $750.00 04/11/2025 Non-covered Recipient Entity
Cct Research Papillion Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294681
Principal investigator 1 Ipsen Innovation $180.00 04/11/2025 Non-covered Recipient Entity
Cct Research Papillion Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294683
Principal investigator 1 ABBVIE INC. $350.00 04/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202475173
Principal investigator 1 ABBVIE INC. $350.00 04/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202475177
Principal investigator 1 Ipsen Innovation $500.00 04/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286688
Principal investigator 1 ABBVIE INC. $2,139.00 04/03/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202472402
Principal investigator 1 ABBVIE INC. $307.05 04/03/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202472405
Principal investigator 1 ABBVIE INC. $924.85 04/03/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202472409
Principal investigator 1 Ipsen Innovation $132.00 04/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286690
Principal investigator 1 Ipsen Innovation $132.00 04/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286692
Principal investigator 1 Ipsen Innovation $33.00 04/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286706
Principal investigator 1 Ipsen Innovation $132.00 04/01/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286708
Principal investigator 1 Ipsen Innovation $2,683.56 03/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286626
Principal investigator 1 Ipsen Innovation $3,250.00 03/19/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286650
Principal investigator 1 Ipsen Innovation $800.00 03/13/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286660
Principal investigator 1 PFIZER INC. $1,250.00 03/13/2025 Non-covered Recipient Entity
Cognitive Clinical Trials LLC
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF RIMEGEPANT IN MIGRAINE PREVENTION IN CHILDREN AND ADOLESCENTS 6 TO 18 YEARS OF AGE No dispute reported 06/30/2026 1228831321
Principal investigator 1 ABBVIE INC. $48.30 03/11/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202462297
Principal investigator 1 Ipsen Innovation $22.88 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286600
Principal investigator 1 Ipsen Innovation $132.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286602
Principal investigator 1 Ipsen Innovation $22.88 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286604
Principal investigator 1 Ipsen Innovation $33.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286606
Principal investigator 1 Ipsen Innovation $22.88 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286608
Principal investigator 1 Ipsen Innovation $33.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286610
Principal investigator 1 Ipsen Innovation $165.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286612
Principal investigator 1 Ipsen Innovation $22.88 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286614
Principal investigator 1 Ipsen Innovation $22.88 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286616
Principal investigator 1 Ipsen Innovation $165.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286618
Principal investigator 1 Ipsen Innovation $132.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286620
Principal investigator 1 Ipsen Innovation $33.01 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286622
Principal investigator 1 Ipsen Innovation $22.88 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286628
Principal investigator 1 Ipsen Innovation $280.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286630
Principal investigator 1 Ipsen Innovation $22.88 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286632
Principal investigator 1 Ipsen Innovation $33.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286634
Principal investigator 1 Ipsen Innovation $22.88 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286636
Principal investigator 1 Ipsen Innovation $33.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286638
Principal investigator 1 Ipsen Innovation $165.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286640
Principal investigator 1 Ipsen Innovation $198.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286644
Principal investigator 1 Ipsen Innovation $132.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286646
Principal investigator 1 Ipsen Innovation $132.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286648
Principal investigator 1 Ipsen Innovation $33.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286652
Principal investigator 1 Ipsen Innovation $132.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286654
Principal investigator 1 Ipsen Innovation $132.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286656
Principal investigator 1 Ipsen Innovation $132.00 03/10/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286658
Principal investigator 1 ABBVIE INC. $8,142.00 03/07/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202460089
Principal investigator 1 ABBVIE INC. $506.65 03/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202456987
Principal investigator 1 Ipsen Innovation $1,000.00 03/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286642
Principal investigator 1 Ipsen Innovation $2,683.56 03/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184286624
Principal investigator 1 Ipsen Innovation $1,008.81 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291970
Principal investigator 1 Ipsen Innovation $2,683.56 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291972
Principal investigator 1 Ipsen Innovation $1,008.81 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291974
Principal investigator 1 Ipsen Innovation $2,098.07 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291976
Principal investigator 1 Ipsen Innovation $1,696.66 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291978
Principal investigator 1 Ipsen Innovation $1,008.81 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291980
Principal investigator 1 Ipsen Innovation $150.48 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291982
Principal investigator 1 Ipsen Innovation $1,008.81 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291984
Principal investigator 1 Ipsen Innovation $1,008.81 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291986
Principal investigator 1 Ipsen Innovation $1,041.48 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291988
Principal investigator 1 Ipsen Innovation $1,008.81 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291990
Principal investigator 1 Ipsen Innovation $1,008.81 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291992
Principal investigator 1 Ipsen Innovation $1,982.18 02/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291994
Principal investigator 1 Ipsen Innovation $450.00 02/14/2025 Non-covered Recipient Entity
Cct Research Papillion Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294677
Principal investigator 1 Ipsen Innovation $150.00 02/14/2025 Non-covered Recipient Entity
Cct Research Papillion Research Center
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184294679
Principal investigator 1 ABBVIE INC. $17,375.00 02/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M23-712 - A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years No dispute reported 06/30/2026 1202447927
Principal investigator 1 ABBVIE INC. $26,358.00 02/06/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202447931
Principal investigator 1 ABBVIE INC. $3,988.20 02/05/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202446345
Principal investigator 1 Ipsen Innovation $1,041.48 01/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291966
Principal investigator 1 Ipsen Innovation $1,041.48 01/27/2025 Non-covered Recipient Entity
Cognitive Clinical Trials
Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study with Extension Phase to Evaluate the Efficacy and Safety of Dysport for the Prevention of Chronic Migraine in Adult Participants No dispute reported 06/30/2026 1184291968
Principal investigator 1 ABBVIE INC. $1,190.00 01/16/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202439597
Principal investigator 1 ABBVIE INC. $48.30 01/09/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202437570
Principal investigator 1 ABBVIE INC. $3,601.55 01/02/2025 Non-covered Recipient Entity
QCARE SITE SERVICES INC
Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17) No dispute reported 06/30/2026 1202434404